Megan Levings

1

Article

0

Comments
Canada once boasted world-class biomanufacturing capacity, particularly in vaccine production. A dose of the measles, mumps and rubella (MMR) vaccination awaits the next patient during a vaccine clinic at Southwestern Public Health in St. Thomas, Ont., on March 2025. THE CANADIAN PRESS/Geoff Robins

Why Canada’s next big infrastructure investment should be in biomanufacturing

Megan Levings, University of British Columbia and Robert A. Holt, Simon Fraser University

As Canada faces renewed trade tensions with the United States, investing in domestic biomanufacturing could strengthen both national security and economic independence.

Contact Megan for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision